Compare Gilead Sciences, Inc. (GILD) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NetApp Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while NetApp Inc. trades at $157.42 (market cap $31.76B). The key difference: Gilead Sciences, Inc. is far larger — about 5.1× NetApp Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NTAP | |
|---|---|---|
Market Cap | $163.51B | $31.76B |
Sector | Health | Technology |
52-Week High | $155.80 | $181.08 |
52-Week Low | $108.22 | $94.11 |
Enterprise Value | $178.05B | $30.91B |
Dividend Yield | 2.49% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NetApp (NTAP) trades at $174.58, up 6.5% over the past 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.43 exceeding the $2.27 estimate. Revenue for 2025 reached $6.57 billion, with a net income margin of 18.43% and a high return on equity of 106.73%. Recent news highlights NetApp's strategic focus on AI infrastructure and a dividend payment scheduled for July 2026.
The outlook for NTAP is positive, driven by enterprise AI demand and consistent earnings performance. Investment opportunities include exposure to data storage growth and strong profitability metrics. Key risks involve high valuation multiples, competitive pressures in the tech sector, and sensitivity to macroeconomic trends affecting IT spending. Analyst consensus is mixed, with a price target of $167.45 below the current price, indicating caution despite overall bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
